PulmonologyNews.net

Pulmonology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Salmeterol"

Results from the COSMOS trial demonstrated that Symbicort Single Inhaler Therapy, ( Budesonide / Formoterol maintenance and reliever therapy ), reduces the risk of severe asthma attack by 25 per ce ...


The use of a class of asthma drugs known as long-acting beta-2 agonists is associated with increased risks of asthma-related deaths. The asthma medications are Salmeterol, which is sold under th ...


Little evidence exists to support the widespread use of bronchodilators to treat children and adults with cystic fibrosis. “ Recurrent wheeze and breathlessness are common in people with cystic fib ...


People with asthma who regularly use Salmeterol ( Serevent ) are at a greater risk of non-fatal serious adverse events than those using placebo. This conclusion was arrived at by a team of Cochrane Re ...


Asthma sufferers who regularly take the beta2-agonist Formoterol ( Foradil ) are more likely to suffer non-fatal serious adverse events than those given placebos. A review carried out by Cochrane Rese ...


Aclidinium bromide ( Eklira, Bretaris ) has been approved since October 2012 for widening the narrowed airways of adults with chronic-obstructive pulmonary disease ( COPD ). The German Institute for Q ...


QVA149 ( Ultibro Breezhaler ) is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive pulmonary disease ( COPD ). It combines Indacaterol (a long acting ...


Fluticasone furoate / Vilanterol ( FF/VI; Relvar Ellipta ) is an inhaled corticosteroid / long-acting beta2-agonist ( ICS / LABA ), recently approved as once-daily maintenance therapy for COPD. Rese ...


QVA149 ( Ultibro Breezhaler ), a novel, once-daily dual bronchodilator containing the long-acting beta2-agonist, Indacaterol and long-acting muscarinic antagonist Glycopyrronium, improves lung functio ...


In patients with symptomatic asthma receiving ICS or ICS+LABA, phase III studies have demonstrated improved lung function with Tiotropium ( Spiriva ) Respimat, a once-daily long-acting anticholinergic ...


Data from phase 3 studies of Tiotropium ( Spiriva ) delivered via the Respimat inhaler in mild, moderate and severe asthma patients were presented at the 2014 American Academy of Allergy, Asthma & ...